Dr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of “Hold” from Analysts

Shares of Dr.Reddy's Laboratories Ltd (NYSE:RDY) have earned an average rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $30.51.

A number of research firms have recently weighed in on RDY. Zacks Investment Research raised Dr.Reddy's Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday. Jefferies Group lowered their price objective on shares of Dr.Reddy's Laboratories from $31.62 to $30.51 and set an “underperform” rating for the company in a research report on Wednesday, November 1st. Finally, Morgan Stanley upgraded shares of Dr.Reddy's Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Thursday, September 21st.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in shares of Dr.Reddy's Laboratories in the 2nd quarter valued at $144,000. Airain ltd bought a new stake in shares of Dr.Reddy's Laboratories in the 2nd quarter valued at $223,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Dr.Reddy's Laboratories in the 2nd quarter valued at $286,000. Stevens Capital Management LP bought a new stake in shares of Dr.Reddy's Laboratories in the 2nd quarter valued at $309,000. Finally, NINE MASTS CAPITAL Ltd bought a new stake in shares of Dr.Reddy's Laboratories in the 3rd quarter valued at $380,000. Institutional investors and hedge funds own 13.71% of the company’s stock.

Dr.Reddy's Laboratories (RDY) opened at $38.73 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.46 and a quick ratio of 1.08. The firm has a market capitalization of $6,440.00, a price-to-earnings ratio of 36.20 and a beta of 0.39. Dr.Reddy's Laboratories has a 12 month low of $29.83 and a 12 month high of $46.95.

TRADEMARK VIOLATION NOTICE: “Dr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of “Hold” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/dr-reddys-laboratories-ltd-rdy-receives-average-recommendation-of-hold-from-analysts.html.

Dr.Reddy's Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply